

## United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER OF PATENTS AND TRADEMARKS Washington, D.C. 20231 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/202,838	01/21/2000	BERTRAND VERDAGUER	TSRI504.1	3464
	7590 08/27/2002			
THE SCRIPPS RESEARCH INSTITUTE 10550 NORTH TORREY.PINES ROAD MAIL DROP TPC 8			EXAMINER	
			ZHOU, SHUBO	
LA JOLLA, C	CA 92037		ART UNIT	' PAPER NUMBER
			1631	,7
			DATE MAILED: 08/27/2002	·

Please find below and/or attached an Office communication concerning this application or proceeding.



## UNITED STATES DEPARTMENT OF COMMERCE Patent and Trader k Office

Address: ASSISTANT COMMISSIONER FOR PATENTS

Washington, D.C. 20231

APPLICATION NO./	FILING DATE	FIRST NAMED INVENTOR /	ATTORNEY DOCKET NO.
		DATES IN DESCRIPTION	
CONTROL NO.		PATENT IN REEXAMINATION	
			·

EXAMINER

ART UNIT PAPER

17

DATE MAILED:

Please find below and/or attached an Office communication concerning this application or proceeding.

## **Commissioner of Patents and Trademarks**

The communication in Paper # 16, filed on 6/4/02, is non-responsive to the prior office actions, mailed 4/22/02 and 9/13/01, because of the following reason:

This application contains sequence disclosures that are encompassed by the definitions for nucleotide and/or amino acid sequences set forth in 37 CFR 1.821(a)(1) and (a) (2). However, this application fails to comply with the requirements of 37 CRF 1.821 through 1.825. Applicants were reminded in the previous Office actions that when a sequence is presented in a drawing regardless of the format or the manner of presentation of that sequence in the drawing, the sequence must still be included in the Sequence Listing and the sequence identifier ("SEQ ID NO:X") must be used, either in the drawing or in the Brief Description of the Drawings. Figures 2 has such sequence. However, the amendment filed on 6/4/02 merely states that the sequence is part of another sequence (SEQ ID NO:2). A separate SEQ ID NO has to be used for each sequence, and the sequence has to be on the Sequence Listing. A paper copy, CRF of a new Sequence Listing containing such sequence, and a statement under 37 CFR 1.821(f) are required. Failure to respond to this requirement may result in abandonment of the instant application.

If a complete reply has not been submitted by the time the period set in the Office communication mailed 4/22/02 has expired, this application will become abandoned under 37 CFR 1.821(g) unless applicant corrects the deficiency and obtains an extension of time under 37 CFR 1.136(a).

Papers related to this application may be submitted to Technical Center 1600 by facsimile transmission. Papers should be faxed to Technical Center 1600 via the PTO Fax Center located in Crystal Mall 1. The faxing of such papers must conform with the notices published in the Official Gazette, 1096 OG 30 (November 15, 1988), 1156 OG 61 (November 16, 1993), and 1157 OG 94 (December 28, 1993)(See 37 CFR § 1.6(d)). The CM1 Fax Center number is either (703) 308-4242 or (703)305-3014.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to: Shubo "Joe" Zhou, Ph.D., whose telephone number is (703) 605-1158. The examiner can normally be reached on Monday-Friday from 8 A.M. to 4 P.M.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Michael Woodward, Ph.D., can be reached on (703) 308-4028. Any inquiry of a general nature or relating to the status of this application should be directed to Patent Analyst Tina Plunkett whose telephone number is 703)-305-3524, or to the Technical Center receptionist whose telephone number is (703) 308-0196.

S. "Joe" Zhou, Ph.D. Patent Examiner

MICHAEL BORIN, PH.D PRIMARY EXAMINER

PTO-90C (Rev.3-98)